The Supervisory Board of BRAIN Biotech AG has appointed Dr. Sven K. Weber to the Executive Board effective October 1, 2026, and named him the future Chairman of the Board (CEO). Mr. Adriaan Moelker, who has led the company as CEO for the past six years, will step down from the Executive Board on September 30, 2026, and will retire as scheduled at the end of his contract term. Mr. Moelker will continue to serve BRAIN Biotech as a senior advisor until the end of his contract term in January 2027.
Dr. Sven K. Weber (44) has held various leadership positions within the BASF Group since 2011. Most recently, as Vice President, he was responsible for BASF Group’s global enzyme business (Global Business Unit Feed Enzymes & Feed Performance Ingredients). In this role, he consistently aligned the business toward innovation-driven, profitable growth and significantly increased revenue and earnings. Previously, as Global Segment Director, he was responsible for the global automotive OEM business at Chemetall GmbH and headed contract research at hte GmbH in Heidelberg, a leading provider of high-throughput solutions for R&D workflows. He began his professional career at Merck Group in Darmstadt. Dr. Weber holds a diploma in chemistry and earned his doctorate from the University of Heidelberg. In addition, he completed an executive program in general management at the SGMI Management Institute in St. Gallen, focusing on strategy, corporate management, and finance.
Dr. Michael Majerus, Chairman of the Supervisory Board of BRAIN Biotech AG, states: “Over the past six years, Adriaan Moelker has repositioned BRAIN Biotech AG as an integrated manufacturing company in the enzyme sector and has successfully monetized projects from the BRAINBioIncubator. For this, I would like to express my sincere thanks to Adriaan on behalf of the entire Supervisory Board. I am now very pleased that, with Dr. Weber, we have been able to bring on board an internationally experienced leader with proven expertise in the industrial enzyme business. He will continue implementing the company’s strategic direction, tap into additional growth potential, and accelerate its operational implementation. On behalf of all members of the Supervisory Board, we wish him a good start and every success.”
Dr. Sven K. Weber, CEO-designate of BRAIN Biotech AG, adds: “I would like to thank the Supervisory Board for the trust they have placed in me. BRAIN Biotech has a strong technological foundation and excellent scientific expertise. Together with the group’s employees I intend to build on this in order to accelerate growth, sustainably strengthen profitability, and bring innovative products to market more quickly for the benefit of our customers. My goal is to develop BRAIN into a leading provider of specialty enzymes in selected application areas and to tap into additional growth potential through the BRAINBioIncubator.”
This leadership transition is significant for BRAIN Biotech as it marks a strategic shift towards leveraging Dr. Weber's experience in the industrial enzyme business to drive growth and innovation. The company, which generated revenue of €49.6 million in the 2024/25 fiscal year with around 280 employees, is focused on specialty enzymes for food and life sciences industries. Dr. Weber's background in enzyme business and R&D aligns with BRAIN Biotech's core activities, including the development of microbial production strains and scalable bioprocesses. For more information about the company, visit www.brain-biotech-group.com.
